Hot Topics Archives | Report Store

Big Pharma Licensing Trends, 2014–18

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

Hot Topics

Hot Topics

Big Pharma Licensing Trends, 2014–18

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

Under the Radar Takeover Targets

JP Morgan Healthcare Conference Review

JP Morgan Healthcare Conference Preview

PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

Pharma-Payer Partnerships in Emerging Markets

Regenerative Medicine Landscape

Immuno-Oncology Deal Trends, 2012–16

Big Pharma Licensing Trends, 2012–16

Mid Pharma Licensing and M&A Trends, 2011–16

Social Media in Pharma

Oncology Market Access in Latin America

Orphan Drug Market Outlook to 2017

Q2 2016 Earnings Previews